tbuckley/cabot-search huggingface dataset:
SP0130 Non-pharmaceutical pain control
Authors: M Mikkelsson
Journal: Annals of the Rheumatic Diseases (2001)

<h3></h3> The lecture will focus on non-pharmaceutical pain control methods in arthritis. In clinics, several pain control methods are available, although there is lack of good randomised controlled trials on different pain control methods. The results of the most interesting studies are summarised. Acute pain is treated partly with different methods than chronic pain. Pain is always subjective. Thus, subjective report about pain is important when evaluating the effectiveness of a pain control method. Important pain control methods are those, which patients can use themselves. These are local cold and heat, relaxation, exercise therapy, collars and splints, and some psychological methods (e.g. autohypnosis). The benefit of these methods is that they are easy available. However, they are dependent on patient's motivation. Health professionals are needed for other pain control methods. Such methods are psychological methods (e.g. cognitive behavioural therapy and hypnosis), education, several physical therapy modalities, exercise therapies and manual physiotherapy, and acupuncture. Pain is often a complex symptom. Usually, several treatment methods, including both pharmaceutical and non-pharmaceutical methods, are needed for achieving a good result.
心臓のカルcalc,筋萎縮症,およびMitotropes JACCレビュー 週間のトピック【JST・京大機械翻訳】
Authors: A Psotka Mitchell, S Gottlieb Stephen, S Francis Gary, A Allen Larry, R Teerlink John, F Adams Kirkwood, M C Rosano Giuseppe, Lancellotti Patrizio
Journal: Journal of the American College of Cardiology (2019)
29P The evolving impact of genomic biomarker landscape in stage II colorectal cancer (CRC)
Authors: G. Arrivi, P. Marchetti, E. Pilozzi, A. Montori, G. Balducci, P. Mercantini, A. Laghi, D. Ierinò, M. Panebianco, F. Mazzuca, M. Roberto
Journal: Annals of Oncology (2020)
Molecular epidemiological typing of Neisseria gonorrhoeae isolates identifies a novel association between genogroup G10557 (G7072) and decreased susceptibility to cefixime, Germany, 2014 to 2017
Authors: Sebastian Banhart, Klaus Jansen, Susanne Buder, Thalea Tamminga, Sébastien Calvignac-Spencer, Tanja Pilz, Andrea Martini, Sandra Dudareva, Sergejs Nikisins, Kerstin Dehmel, Gabriele Zuelsdorf, Eva Guhl, Ingeborg Graeber, Peter K Kohl, Magnus Unemo, Viviane Bremer, Dagmar Heuer
Journal: Eurosurveillance (2020)

Background Emerging antimicrobial resistance (AMR) challenges gonorrhoea treatment and requires surveillance. Aim This observational study describes the genetic diversity of Neisseria gonorrhoeae isolates in Germany from 2014 to 2017 and identifies N. gonorrhoeae multi-antigen sequence typing (NG-MAST) genogroups associated with AMR or some patient demographics. Methods 1,220 gonococcal isolates underwent AMR testing and NG-MAST. Associations between genogroups and AMR or sex/age of patients were statistically assessed. Results Patients’ median age was 32 years (interquartile range: 25–44); 1,078 isolates (88.4%) originated from men. In total, 432 NG-MAST sequence types including 156 novel ones were identified, resulting in 17 major genogroups covering 59.1% (721/1,220) of all isolates. Genogroups G1407 and G10557 (G7072) were significantly associated with decreased susceptibility to cefixime (Kruskal–Wallis chi-squared: 549.3442, df: 16, p &lt; 0.001). Their prevalences appeared to decline during the study period from 14.2% (15/106) to 6.2% (30/481) and from 6.6% (7/106) to 3.1% (15/481) respectively. Meanwhile, several cefixime susceptible genogroups’ prevalence seemed to increase. Proportions of isolates from men differed among genogroups (Fisher’s exact test, p &lt; 0.001), being e.g. lower for G25 (G51) and G387, and higher for G5441 and G2992. Some genogroups differed relative to each other in affected patients’ median age (Kruskal–Wallis chi-squared: 47.5358, df: 16, p &lt; 0.001), with e.g. G25 (G51) and G387 more frequent among ≤ 30 year olds and G359 and G17420 among ≥ 40 year olds. Conclusion AMR monitoring with molecular typing is important. Dual therapy (ceftriaxone plus azithromycin) recommended in 2014 in Germany, or only the ceftriaxone dose of this therapy, might have contributed to cefixime-resistant genogroups decreasing.
Maternal Antenatal Corticosteroid Treatment and Childhood Mental and Behavioral Disorders
Authors: Cynthia Gyamfi-Bannerman, George R. Saade, Dwight J. Rouse
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response
Authors: Thibault Fiolet, Anthony Guihur, Mathieu Edouard Rebeaud, Matthieu Mulot, Nathan Peiffer-Smadja, Yahya Mahamat-Saleh
Journal: Clinical Microbiology and Infection (2020)
SAT0225 A novel web based rheumatology educational resource – interactive computerised case studies for undergraduate teaching
Authors: AS Wilson, GD Kitas, SJ Bowman, P Llewellyn, PA Bacon, SP Young
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> We have applied the principal that the undergraduate curriculum should have a reduced burden of factual information and learning through curiosity should be encouraged,<sup>1</sup> to the education of our rheumatology students. <h3>Objectives</h3> We have applied advances in computer technology to develop a web based educational strategy and evaluated its use from the perspective of the student/user. <h3>Methods</h3> A teaching needs assessment conducted on a cohort of 30 students prompted the development of a novel interactive case studies programme, accessible through the internet. This programme utilises active server page technology (TM) reading from a database of case study information (anonymised). The user can select predefined questions, perform a virtual physical examination and gain diagnostic information by requesting laboratory tests. The user is then required to make a diagnosis and select an appropriate treatment regimen for that patient. To introduce realism, performance is evaluated by an indication of the patients outcome and the financial expenditure incurred for their consultation. Usage data was collected from online questionnaire and by computer generated log file analysis. <h3>Results</h3> All students agreed that computer based learning was a useful adjunct to traditional teaching and greater than 95% expressed strong support for the use of computerised case studies. All questionnaire respondents (n = 17) agreed that the computer programme was well organised, realistic and that they had learnt from the experience. Although this teaching aid is primarily aimed at our local teaching hospitals, log file analysis indicates that there have been 239 visits to the site (181 unique) from North America, Europe, Asia and Oceania, suggesting a widespread interest. <h3>Conclusion</h3> This novel interactive web based programme, based on real life patient information, will serve as a teaching resource for our allied hospitals and introduce some variety into more formal teaching practices by promoting self-learning. The techniques employed could be adaptable to other situations which would benefit from increased user interaction and in a dispersed learning environment. <h3>Reference</h3> General Medical Council report “Tomorrow’s Doctors”, 1993
Letter by Siontis and Räber Regarding Article, “Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART)”
Authors: George C.M. Siontis, Lorenz Räber
Journal: Circulation (2020)
The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019)
Authors: Vivian Chua, Jane Mattei, Anna Han, Lauren Johnston, Kyleigh LiPira, Sara M. Selig, Richard D. Carvajal, Andrew E. Aplin, Sapna P. Patel
Journal: Clinical Cancer Research (2020)

Uveal melanoma is a rare cancer in adults, but its treatment is one of the clinical unmet needs in the melanoma field. Metastatic disease develops in approximately 50% of patients and is associated with poor survival due to the lack of effective treatment options. It provides a paradigm for cancers that show evidence of aberrant G protein-coupled receptor signaling, tumor dormancy, and liver-selective metastatic tropism and are associated with the loss of the BAP1 tumor suppressor. At the Melanoma Research Foundation CURE OM Science Meeting at the Society for Melanoma Research Meeting held in Utah on November 20, 2019, clinicians and researchers presented findings from their studies according to three themes within uveal melanoma: (i) ongoing clinical trials, (ii) molecular determinants, and (iii) novel targets that could be translated into clinical trials. This meeting underscored the high interest in the uveal melanoma research field and the unmet need for effective treatment strategies for late-stage disease. Findings from ongoing clinical trials are promising, and multiple studies show how novel combinatorial strategies increase response rates. Novel targets and tumor vulnerabilities identified bioinformatically or through high-throughput screens also reveal new opportunities to target uveal melanoma. The future directions pursued by the uveal melanoma research field will likely have an impact on other cancer types that harbor similar genetic alterations and/or show similar biological properties.
45P Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Pooled analysis of clinical trials and early access programs
Authors: M. Droz Dit Busset, W.L. Shaib, W.P. Harris, N. Damjanov, M. Borad, A. Vogel, J.A. Bridgewater, L. Sellmann, V. Dadduzio, M. Borner, J. Snider, F. Cantero, M. Saulay, S. Braun, V. Mazzaferro, M. Javle
Journal: Annals of Oncology (2020)
Cryptococcal infection in HIV-infected patients with CD4+ T-cell counts under 100/μL diagnosed in a high-income country: a multicentre cohort study
Authors: María Asunción Pérez-Jacoiste Asín, Otilia Bisbal, José Antonio Iribarren, Alfredo Pérez-Rivilla, Rafael Mican, Fernando Dronda, Carmen María González-Domenech, David Vinuesa-García, Juan Macías, Carlos Lumbreras, Santiago Moreno, Rafael Rubio
Journal: Clinical Microbiology and Infection (2020)
THU0598 A CASE REPORT ON A RARE PRESENTATION OF GOUT INVOLVING THE PATELLAR TENDON
Authors: A. Munir, C. Sheehy
Journal: Annals of the Rheumatic Diseases (2020)

Background: Gout is an inflammatory arthropathy associated with long-standing hyperuricemia. The first metatarsophalangeal joint is the most commonly involved joint, although gout is often polyarticular. Involvement of tendons has been described, but is rare. We report a case of gout involving the inferior portion of the patellar tendon. Objectives: A Case report to highlight a rare presentation of gout. Methods: A 50 year old male presented to the Rheumatology emergency clinic with severe right knee pain, unable to weight bear. He had been recently diagnosed with Sero negative Inflammatory Arthritis and treated with Methotrexate for 4 months. He had presented one week previously to the general medical team on call with similar but less severe pain. He was discharged on steroids, which were of no significant benefit. The pain progressively worsened to the extent that he was not able to bear weight on the right knee. He denied pain or swelling of any other joint. On examination of his right knee, it was extremely tender, slightly erythematous with increased local temperature. There was no arthritis in any other joint and there were no tophi. Joint aspiration was attempted but there was no fluid. He was admitted with query Septic arthritis and started on intravenous antibiotics. Uric acid level was 583u/l. US of the knee showed small fluid in the pre patellar bursa.Orthopaedic team was involved and he was taken to the operation theatre. Knee joint was aspirated which was negative for crystals and there was no growth on cultures. He ultimately had an MRI of his right knee which showed significant soft tissue oedema and abnormality in the patellar tendon. MRI of Rt knee showing marked soft tissue edema (arrow) Targeted US of the knee done by a consultant rheumatologist showed significant changes in the inferior portion of the patellar tendon consistent with infiltration. The external tendon boundaries were normal. It was thought to be likely that these represented gouty tophi. USG of the rt knee showing infiltrates in the inferior portion of patellar tendon with increased Doppler flow He went on to have a patellar tendon biopsy which has shown changes consistent with gout. He was started on Colchicine 0.5mg bd leaving the hospital and Allopurinol was started two weeks later. Results: He was seen in the clinic as follow up with complete resolution of his pain. Methotrexate was stopped. He has reported no flares and Allopurinol is being titrated up to achieve serum uric acid concentration &lt;300u/l. Conclusion: The most important finding in this case report is that interstitial gouty tophi of the patellar tendon, can cause debilitating symptoms and can prove difficult to diagnose and treat. References: [1]Roddy E, Choi H K. Epidemiology of gout. Rheum Dis Clin North Am. 2014;40(02):155–175. [2]Forbess L J, Fields T R. The broad spectrum of urate crystal deposition: unusual presentations of gouty tophi. Semin Arthritis Rheum. 2012;42(02):146–154. Disclosure of Interests: None declared
34P N-glycosylation status of membrane phosphate transporter NaPi2b is crucial for its epitope recognition by monoclonal antibody in tumour cells
Authors: R. Kiyamova, L.F. Minigulova, V. Skripova, A. Nurgalieva, D. Reshetnikova, L. Savinska, V. Filonenko, M. Bogdanov
Journal: Annals of Oncology (2020)
Bioinspired stratified electrowritten fiber-reinforced hydrogel constructs with layer-specific induction capacity for functional osteochondral regeneration
Authors: Zhiguang Qiao, Meifei Lian, Yu Han, Binbin Sun, Xing Zhang, Wenbo Jiang, Huiwu Li, Yongqiang Hao, Kerong Dai
Journal: Biomaterials (2020)
Real-World Effectiveness and Safety of Tofacitinib in Crohn’s Disease and IBD-U: A Multicenter Study From the TROPIC Consortium
Authors: Marc Fenster, Quazim A. Alayo, Aava Khatiwada, Wenfei Wang, Christina Dimopoulos, Alexandra Gutierrez, Matthew A. Ciorba, George P. Christophi, Robert P. Hirten, Christina Ha, Poonam Beniwal-Patel, Benjamin L. Cohen, Gaurav Syal, Andres Yarur, Anish Patel, Jean-Frederic Colombel, Joel Pekow, Ryan C. Ungaro, David T. Rubin, Parakkal Deepak
Journal: Clinical Gastroenterology and Hepatology (2020)
OP0095 Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor-alfa monoclonal antibody (infliximab) in persistently active refractory juvenile idiopathic (chronic) arthritis. an one year open prospective pilot study
Authors: V Gerloni, I Pontikaki, F Desiati, E Lupi, M Gattinara, F Fantini
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> An open prospective trial was carried out in a young population affected by severe, refractory, polyarthritic JIA to evaluate the efficacy and safety of Infliximab (Remicade). <h3>Methods</h3> We enrolled 17 females, median age at the start of the therapy 22.9 yrs (8–33), median onset age 3 yrs (1–16), median disease duration 15.6 yrs (5–31). All patients had been previously treated with more than one DMARD (median number 3.5/patient, as mono or combined therapy). All patients had still active disease: number of active joints (median 5.5), ESR (median 59.5 mm/hr), CRP (median 4.7 mg/dl), physician global evaluation (median VAS 45.5), HAQ (median D. I. 1.13). 14 patients were still on corticosteroids (median 0.11 mg/kg). All patients discontinued any other DMARD aside from s.c. MTX (median weekly dose 15 mg, range 5–25) and continued with previous NSAIDs and corticosteroids. Infliximab was administrated as a single infusion of 3 mg/kg at time 0 and at weeks 2, 6, 14, 22, 30. <h3>Results</h3> Until now all 17 pts have received the first 2 infusions, 15 pts 3 infusions, 9 pts 6 infusions, 8 pts 7 infusions, 2 pts 8 infusions and 1 pt 10 infusions. One patient withdrew because of a severe adverse event (hypersensitivity reaction at the third infusion). Since the 1st infusion, all 17 patients achieved a very good response (50% reduction in number of active joints, ESR, CRP, VAS). A statistically significant improvement of the following parameters was observed at the 6th infusion assessment (evaluation on 9 patients who completed 30 weeks = 5 months of therapy): the median number of active joints decreased from 5 to 0; ESR decreased from a median of 65 to 23 mm/hr and CRP decreased from a median of 4.6 to 0.4 mg/dl; the median score of the VAS (physician global evaluation) decreased from a 65 to 2. Furthermore after 6 months of therapy we observed a trend to improvement in all scales of SF36 (assessment of the quality of life). An eleven-year-old girl with chronic active uveitis showed a great improvement of the visus. <h3>Conclusion</h3> These data suggest that Infliximab can significantly and promptly reduce disease activity and improve the quality of life of patients affected by persistently active and refractory JIA. However more data are needed to evaluate its efficacy and safety as a long-term therapy.
Budesonide–formoterol reliever therapy in intermittent <i>versus</i> mild persistent asthma
Authors: Alberto Papi, Irene Braithwaite, Stefan Ebmeier, Robert J. Hancox, Tim Harrison, Mark Holliday, Claire Houghton, Luca Morandi, Karen Oldfield, Ian D. Pavord, Helen K. Reddel, Mathew Williams, Mark Weatherall, Richard Beasley
Journal: European Respiratory Journal (2020)

<b>These <i>post hoc</i> analyses of NovelSTART provide the first evidence that the exacerbation risk reduction with budesonide–formoterol reliever therapy <i>versus</i> salbutamol reliever therapy is similar in adults with intermittent and mild persistent asthma</b>https://bit.ly/3iiRKqR
Patient-Specific Induced Pluripotent Stem Cells Implicate Intrinsic Impaired Contractility in Hypoplastic Left Heart Syndrome
Authors: Sharon L. Paige, Francisco X. Galdos, Soah Lee, Elizabeth T. Chin, Sara Ranjbarvaziri, Dries A.M. Feyen, Adrija K. Darsha, Sidra Xu, Julia A. Ryan, Aimee L. Beck, M. Yasir Qureshi, Yifei Miao, Mingxia Gu, Daniel Bernstein, Timothy J. Nelson, Mark Mercola, Marlene Rabinovitch, Euan A. Ashley, Victoria N. Parikh, Sean M. Wu
Journal: Circulation (2020)
Thrombomodulin ameliorates transforming growth factor-β1–mediated chronic kidney disease via the G-protein coupled receptor 15/Akt signal pathway
Authors: Atsuro Takeshita, Taro Yasuma, Kota Nishihama, Corina N. D’Alessandro-Gabazza, Masaaki Toda, Toshiaki Totoki, Yuko Okano, Akihiro Uchida, Ryo Inoue, Liqiang Qin, Shujie Wang, Valeria Fridman D’Alessandro, Tetsu Kobayashi, Yoshiyuki Takei, Akira Mizoguchi, Yutaka Yano, Esteban C. Gabazza
Journal: Kidney International (2020)

Kidney fibrosis is the common consequence of chronic kidney diseases that inexorably progresses to end-stage kidney disease with organ failure treatable only with replacement therapy. Since transforming growth factor-β1 is the main player in the pathogenesis of kidney fibrosis, we posed the hypothesis that recombinant thrombomodulin can ameliorate transforming growth factor-β1-mediated progressive kidney fibrosis and failure. To interrogate our hypothesis, we generated a novel glomerulus-specific human transforming growth factor-β1 transgenic mouse to evaluate the therapeutic effect of recombinant thrombomodulin. This transgenic mouse developed progressive glomerular sclerosis and tubulointerstitial fibrosis with kidney failure. Therapy with recombinant thrombomodulin for four weeks significantly inhibited kidney fibrosis and improved organ function compared to untreated transgenic mice. Treatment with recombinant thrombomodulin significantly inhibited apoptosis and mesenchymal differentiation of podocytes by interacting with the G-protein coupled receptor 15 to activate the Akt signaling pathway and to upregulate the expression of anti-apoptotic proteins including survivin. Thus, our study strongly suggests the potential therapeutic efficacy of recombinant thrombomodulin for the treatment of chronic kidney disease and subsequent organ failure.
Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer—Letter
Authors: David Birnbaum, Pascal Finetti, Daniel Birnbaum, F. Bertucci
Journal: Clinical Cancer Research (2020)

Moroz and colleagues showed the antitumor activity of radiolabeled antibodies directed against CDCP1 in preclinical models of pancreatic carcinoma ([1][1]). Pancreatic carcinoma is one of the most aggressive human cancers. Complete surgical resection followed by chemotherapy is the only available